CDH2 and cancer: During epithelial–mesenchymal transition (EMT), a process frequently observed in cancer progression, cancer cells commonly down-regulate the expression of E-cadherin, while concurrently up-regulating other cadherins such as N-cadherin and P-cadherin [71,72,73].